A small tool to view real-world ActivityPub objects as JSON! Enter a URL
or username from Mastodon or a similar service below, and we'll send a
request with
the right
Accept
header
to the server to view the underlying object.
{
"@context": "https://www.w3.org/ns/activitystreams",
"type": "OrderedCollectionPage",
"orderedItems": [
{
"type": "Create",
"actor": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"object": {
"type": "Note",
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1221912002823585792",
"attributedTo": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"content": "Lockdown could be over if we actually followed the science.<br />This panel is comprised of:<br />1. Dr Tess Lawrie (MBBCh, DFSRH, PhD) 🇬🇧 , Director of the Evidence-Based Medical Consultancy Ltd- which conducts industry independent medical evidence synthesis to support international clinical practice guidelines AND has both the NHS and WHO as clients<br />2. Mobeen Syed M.D., M.S. 🇺🇸 , graduated from King Edward Medical University in 1994. After practising clinical medicine for a few years, he continued his studies in Computer Science with the goal of merging innovative technologies and healthcare.<br />3. Prof. Eli Schwartz, MD, DTMH 🇮🇱. The Centre for Geographic Medicine and Tropical Diseases, The Chaim Sheba Medical Centre, Israel <br />4. Hector Carvallo, MD 🇦🇷- Professor of Medicine, Adolfo Ibanez University y Universidad Mayor, former director of Ezeiza Public Hospital, Argentina<br />5. Marc Wathelet, PhD 🇧🇪- Molecular and cellular biologist, Coronavirus specialist, Belgium. Specialises in the study of respiratory viruses.<br />6. Dr. Pierre Kory, MD, MPA 🇺🇸 -former Chief of the Critical Care Service and Medical Director of the Trauma and Life Support Center at the University of Wisconsin. He is a Board-Certified Specialist in Critical Care Medicine, Pulmonary Diseases, and Internal Medicine",
"to": [
"https://www.w3.org/ns/activitystreams#Public"
],
"cc": [
"https://www.minds.com/api/activitypub/users/1196069879724122124/followers"
],
"tag": [],
"url": "https://www.minds.com/newsfeed/1221912002823585792",
"published": "2021-03-25T20:02:02+00:00",
"source": {
"content": "Lockdown could be over if we actually followed the science.\nThis panel is comprised of:\n1. Dr Tess Lawrie (MBBCh, DFSRH, PhD) 🇬🇧 , Director of the Evidence-Based Medical Consultancy Ltd- which conducts industry independent medical evidence synthesis to support international clinical practice guidelines AND has both the NHS and WHO as clients\n2. Mobeen Syed M.D., M.S. 🇺🇸 , graduated from King Edward Medical University in 1994. After practising clinical medicine for a few years, he continued his studies in Computer Science with the goal of merging innovative technologies and healthcare.\n3. Prof. Eli Schwartz, MD, DTMH 🇮🇱. The Centre for Geographic Medicine and Tropical Diseases, The Chaim Sheba Medical Centre, Israel \n4. Hector Carvallo, MD 🇦🇷- Professor of Medicine, Adolfo Ibanez University y Universidad Mayor, former director of Ezeiza Public Hospital, Argentina\n5. Marc Wathelet, PhD 🇧🇪- Molecular and cellular biologist, Coronavirus specialist, Belgium. Specialises in the study of respiratory viruses.\n6. Dr. Pierre Kory, MD, MPA 🇺🇸 -former Chief of the Critical Care Service and Medical Director of the Trauma and Life Support Center at the University of Wisconsin. He is a Board-Certified Specialist in Critical Care Medicine, Pulmonary Diseases, and Internal Medicine",
"mediaType": "text/plain"
}
},
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1221912002823585792/activity"
},
{
"type": "Create",
"actor": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"object": {
"type": "Note",
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1203992181185982464",
"attributedTo": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"content": "Mind the clickbait headline.<br />Host Liam Bartlett of 6pr News Talk Radio in Perth, Australia speaks to Robert Clancy (B. Sc. Med, MB.BS, PhD, FRACP, FRCPA) who is Emeritus Professor of Pathology at the University of Newcastle Medical School and member of the Australian Academy of Science’s COVID-19 Expert Database about the efficacy of IVM to tackle SAS CoV2.<br /><br /><a href=\"https://www.6pr.com.au/the-worst-24-hours-of-my-life-immunologist-responds-to-craig-kelly-controversy/\" target=\"_blank\">https://www.6pr.com.au/the-worst-24-hours-of-my-life-immunologist-responds-to-craig-kelly-controversy/</a> ",
"to": [
"https://www.w3.org/ns/activitystreams#Public"
],
"cc": [
"https://www.minds.com/api/activitypub/users/1196069879724122124/followers"
],
"tag": [],
"url": "https://www.minds.com/newsfeed/1203992181185982464",
"published": "2021-02-04T09:15:05+00:00",
"source": {
"content": "Mind the clickbait headline.\nHost Liam Bartlett of 6pr News Talk Radio in Perth, Australia speaks to Robert Clancy (B. Sc. Med, MB.BS, PhD, FRACP, FRCPA) who is Emeritus Professor of Pathology at the University of Newcastle Medical School and member of the Australian Academy of Science’s COVID-19 Expert Database about the efficacy of IVM to tackle SAS CoV2.\n\nhttps://www.6pr.com.au/the-worst-24-hours-of-my-life-immunologist-responds-to-craig-kelly-controversy/ ",
"mediaType": "text/plain"
}
},
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1203992181185982464/activity"
},
{
"type": "Create",
"actor": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"object": {
"type": "Note",
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1202857568228155392",
"attributedTo": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"content": "How does <a href=\"https://www.minds.com/search?f=top&t=all&q=ivermectin\" title=\"#ivermectin\" class=\"u-url hashtag\" target=\"_blank\">#ivermectin</a> work against SARS CoV-2?<br />Dr Been explains it's mechanism of action.<br /><br /><a href=\"https://youtu.be/GZoBAuR4ajs\" target=\"_blank\">https://youtu.be/GZoBAuR4ajs</a>",
"to": [
"https://www.w3.org/ns/activitystreams#Public"
],
"cc": [
"https://www.minds.com/api/activitypub/users/1196069879724122124/followers"
],
"tag": [],
"url": "https://www.minds.com/newsfeed/1202857568228155392",
"published": "2021-02-01T06:06:32+00:00",
"source": {
"content": "How does #ivermectin work against SARS CoV-2?\nDr Been explains it's mechanism of action.\n\nhttps://youtu.be/GZoBAuR4ajs",
"mediaType": "text/plain"
}
},
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1202857568228155392/activity"
},
{
"type": "Announce",
"actor": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"object": {
"type": "Note",
"id": "https://www.minds.com/api/activitypub/users/755719262970060808/entities/urn:activity:1202269500217040896",
"attributedTo": "https://www.minds.com/api/activitypub/users/755719262970060808",
"content": "Mectizan:registered: a.k.a. IVERMECTIN or Stromectol:registered:<br /> This 20 minute documentary chonicles the successful fight against river blindness in West Africa.. It features President Jimmy Carter and the voice of Ozzie Davis.<br />For centuries, river blindness (also known as onchocerciasis) plagued remote communities in Africa, Latin America, and Yemen. Before effective treatment was available, infection caused severe itching, visual impairment, and—ultimately—blindness. Communities abandoned farmlands in fertile areas because nearby rivers were home to the blackflies that transmit the disease.<br />In the 1970s, Dr. William Campbell of Merck Research Laboratories suggested the use of ivermectin (later named Mectizan) for river blindness in humans. Following the breakthrough lab work by Dr. Campbell (who in 2015 was named a Nobel Laureate) and his team, another Merck researcher, Dr. Mohammed Aziz, championed the clinical development of Mectizan. In the 1980s, Dr. Aziz led the collaboration with the World Health Organization (WHO) to design and implement the trials in West Africa that proved the effectiveness of the drug against river blindness.<br />In 1987, Merck & Co., Inc., Kenilworth, N.J., U.S.A.* committed to donating Mectizan – as much as needed for as long as needed – with the goal to help control river blindness. Today, this unprecedented drug donation is helping to eliminate transmission of the disease – an unfathomable concept when Merck first donated Mectizan.<br />The program reaches more than 300 million people annually, and more than 2.7 billion treatments have been donated since 1987.<br /><a href=\"https://vimeo.com/370322208\" target=\"_blank\">https://vimeo.com/370322208</a>",
"to": [
"https://www.w3.org/ns/activitystreams#Public"
],
"cc": [
"https://www.minds.com/api/activitypub/users/755719262970060808/followers"
],
"tag": [],
"url": "https://www.minds.com/newsfeed/1202269500217040896",
"published": "2021-01-30T15:09:45+00:00",
"source": {
"content": "Mectizan:registered: a.k.a. IVERMECTIN or Stromectol:registered:\n This 20 minute documentary chonicles the successful fight against river blindness in West Africa.. It features President Jimmy Carter and the voice of Ozzie Davis.\nFor centuries, river blindness (also known as onchocerciasis) plagued remote communities in Africa, Latin America, and Yemen. Before effective treatment was available, infection caused severe itching, visual impairment, and—ultimately—blindness. Communities abandoned farmlands in fertile areas because nearby rivers were home to the blackflies that transmit the disease.\nIn the 1970s, Dr. William Campbell of Merck Research Laboratories suggested the use of ivermectin (later named Mectizan) for river blindness in humans. Following the breakthrough lab work by Dr. Campbell (who in 2015 was named a Nobel Laureate) and his team, another Merck researcher, Dr. Mohammed Aziz, championed the clinical development of Mectizan. In the 1980s, Dr. Aziz led the collaboration with the World Health Organization (WHO) to design and implement the trials in West Africa that proved the effectiveness of the drug against river blindness.\nIn 1987, Merck & Co., Inc., Kenilworth, N.J., U.S.A.* committed to donating Mectizan – as much as needed for as long as needed – with the goal to help control river blindness. Today, this unprecedented drug donation is helping to eliminate transmission of the disease – an unfathomable concept when Merck first donated Mectizan.\nThe program reaches more than 300 million people annually, and more than 2.7 billion treatments have been donated since 1987.\nhttps://vimeo.com/370322208",
"mediaType": "text/plain"
}
},
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1202639363123937280/activity",
"to": [
"https://www.w3.org/ns/activitystreams#Public"
],
"cc": [
"https://www.minds.com/api/activitypub/users/755719262970060808",
"https://www.minds.com/api/activitypub/users/1196069879724122124/followers"
]
},
{
"type": "Create",
"actor": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"object": {
"type": "Note",
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1201869692410736640",
"attributedTo": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"content": "<a href=\"https://www.minds.com/newsfeed/1201869692410736640\" target=\"_blank\">https://www.minds.com/newsfeed/1201869692410736640</a>",
"to": [
"https://www.w3.org/ns/activitystreams#Public"
],
"cc": [
"https://www.minds.com/api/activitypub/users/1196069879724122124/followers"
],
"tag": [],
"url": "https://www.minds.com/newsfeed/1201869692410736640",
"published": "2021-01-29T12:41:03+00:00",
"source": {
"content": "https://www.minds.com/newsfeed/1201869692410736640",
"mediaType": "text/plain"
}
},
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1201869692410736640/activity"
},
{
"type": "Create",
"actor": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"object": {
"type": "Note",
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1201219708668530688",
"attributedTo": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"content": "<a class=\"u-url mention\" href=\"https://www.minds.com/sahari_ivsa\" target=\"_blank\">@sahari_ivsa</a> responds to the SAHPRAs limited decision to allow access to <a href=\"https://www.minds.com/search?f=top&t=all&q=ivermectin\" title=\"#ivermectin\" class=\"u-url hashtag\" target=\"_blank\">#ivermectin</a> through compassionate controlled access.<br /><br /> <a href=\"https://www.minds.com/search?f=top&t=all&q=ivermectin4sa\" title=\"#ivermectin4sa\" class=\"u-url hashtag\" target=\"_blank\">#ivermectin4sa</a> <a href=\"https://www.minds.com/search?f=top&t=all&q=right2health\" title=\"#right2health\" class=\"u-url hashtag\" target=\"_blank\">#right2health</a> ",
"to": [
"https://www.w3.org/ns/activitystreams#Public"
],
"cc": [
"https://www.minds.com/api/activitypub/users/1196069879724122124/followers"
],
"tag": [],
"url": "https://www.minds.com/newsfeed/1201219708668530688",
"published": "2021-01-27T17:38:14+00:00",
"source": {
"content": "@sahari_ivsa responds to the SAHPRAs limited decision to allow access to #ivermectin through compassionate controlled access.\n\n #ivermectin4sa #right2health ",
"mediaType": "text/plain"
}
},
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1201219708668530688/activity"
},
{
"type": "Create",
"actor": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"object": {
"type": "Note",
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1200914558230765568",
"attributedTo": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"content": "Business Day TV host, Michael Avery, discusses Ivermectin with <a class=\"u-url mention\" href=\"https://www.minds.com/sahari_ivmsa\" target=\"_blank\">@sahari_ivmsa</a> founder <a class=\"u-url mention\" href=\"https://www.minds.com/shabnampalesamohamed\" target=\"_blank\">@shabnampalesamohamed</a>, Dr Naseeba Kathrada, Dr Boitumelo Semete Makokotlela & Daniel Eloff, one of the attorneys representing Afriforum. <br /><br /><br /><br /><br /><br /><br /><br /><br /><a href=\"https://youtu.be/OwnP4zqfIpE\" target=\"_blank\">https://youtu.be/OwnP4zqfIpE</a>",
"to": [
"https://www.w3.org/ns/activitystreams#Public"
],
"cc": [
"https://www.minds.com/api/activitypub/users/1196069879724122124/followers"
],
"tag": [
{
"type": "Mention",
"href": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"name": "@sahari_ivmsa"
},
{
"type": "Mention",
"href": "https://www.minds.com/api/activitypub/users/1196105578301104139",
"name": "@shabnampalesamohamed"
}
],
"url": "https://www.minds.com/newsfeed/1200914558230765568",
"published": "2021-01-26T21:25:42+00:00",
"source": {
"content": "Business Day TV host, Michael Avery, discusses Ivermectin with @sahari_ivmsa founder @shabnampalesamohamed, Dr Naseeba Kathrada, Dr Boitumelo Semete Makokotlela & Daniel Eloff, one of the attorneys representing Afriforum. \n\n\n\n\n\n\n\n\nhttps://youtu.be/OwnP4zqfIpE",
"mediaType": "text/plain"
}
},
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1200914558230765568/activity"
},
{
"type": "Announce",
"actor": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"object": {
"type": "Note",
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1200534754142003200",
"attributedTo": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"content": "Discussion with Dr Tess Lawrie, director of the Evidence Based Medical Consultancy, on the efficacy of <a href=\"https://www.minds.com/search?f=top&t=all&q=Ivermectin\" title=\"#Ivermectin\" class=\"u-url hashtag\" target=\"_blank\">#Ivermectin</a><br /><br /><br /><a href=\"https://youtu.be/rHPkR6QRcCc\" target=\"_blank\">https://youtu.be/rHPkR6QRcCc</a>",
"to": [
"https://www.w3.org/ns/activitystreams#Public"
],
"cc": [
"https://www.minds.com/api/activitypub/users/1196069879724122124/followers"
],
"tag": [],
"url": "https://www.minds.com/newsfeed/1200534754142003200",
"published": "2021-01-25T20:16:30+00:00",
"source": {
"content": "Discussion with Dr Tess Lawrie, director of the Evidence Based Medical Consultancy, on the efficacy of #Ivermectin\n\n\nhttps://youtu.be/rHPkR6QRcCc",
"mediaType": "text/plain"
}
},
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1200534840149688320/activity",
"to": [
"https://www.w3.org/ns/activitystreams#Public"
],
"cc": [
"https://www.minds.com/api/activitypub/users/1196069879724122124",
"https://www.minds.com/api/activitypub/users/1196069879724122124/followers"
]
},
{
"type": "Create",
"actor": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"object": {
"type": "Note",
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1200534754142003200",
"attributedTo": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"content": "Discussion with Dr Tess Lawrie, director of the Evidence Based Medical Consultancy, on the efficacy of <a href=\"https://www.minds.com/search?f=top&t=all&q=Ivermectin\" title=\"#Ivermectin\" class=\"u-url hashtag\" target=\"_blank\">#Ivermectin</a><br /><br /><br /><a href=\"https://youtu.be/rHPkR6QRcCc\" target=\"_blank\">https://youtu.be/rHPkR6QRcCc</a>",
"to": [
"https://www.w3.org/ns/activitystreams#Public"
],
"cc": [
"https://www.minds.com/api/activitypub/users/1196069879724122124/followers"
],
"tag": [],
"url": "https://www.minds.com/newsfeed/1200534754142003200",
"published": "2021-01-25T20:16:30+00:00",
"source": {
"content": "Discussion with Dr Tess Lawrie, director of the Evidence Based Medical Consultancy, on the efficacy of #Ivermectin\n\n\nhttps://youtu.be/rHPkR6QRcCc",
"mediaType": "text/plain"
}
},
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1200534754142003200/activity"
},
{
"type": "Create",
"actor": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"object": {
"type": "Note",
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1198373895515340800",
"attributedTo": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"content": "\"A comprehensive and detailed review “Ivermectin Reduces the Risk of Death from COVID-19” (January 3:2021) by T Lawrie, from The Evidence-based Medicine Consultancy, confirmed the view of the US “Front Line COVID-19 Critical Care Alliance” that the evidence on IVM “demonstrates a strong signal of therapeutic efficacy” recommending its global adoption for prophylaxis and treatment of COVID-19. Seventeen treatment and prophylaxis studies were critically analysed (nine of which were RCTs). “Moderate Certainty Evidence” in RCTs showed IVM reduced death by an an average of 83 per cent (65-92. 95 per cent confidence limits).\"<br /><br /><a href=\"https://quadrant.org.au/opinion/qed/2021/01/covid-19-a-realistic-approach-to-community-management/\" target=\"_blank\">https://quadrant.org.au/opinion/qed/2021/01/covid-19-a-realistic-approach-to-community-management/</a>",
"to": [
"https://www.w3.org/ns/activitystreams#Public"
],
"cc": [
"https://www.minds.com/api/activitypub/users/1196069879724122124/followers"
],
"tag": [],
"url": "https://www.minds.com/newsfeed/1198373895515340800",
"published": "2021-01-19T21:10:01+00:00",
"source": {
"content": "\"A comprehensive and detailed review “Ivermectin Reduces the Risk of Death from COVID-19” (January 3:2021) by T Lawrie, from The Evidence-based Medicine Consultancy, confirmed the view of the US “Front Line COVID-19 Critical Care Alliance” that the evidence on IVM “demonstrates a strong signal of therapeutic efficacy” recommending its global adoption for prophylaxis and treatment of COVID-19. Seventeen treatment and prophylaxis studies were critically analysed (nine of which were RCTs). “Moderate Certainty Evidence” in RCTs showed IVM reduced death by an an average of 83 per cent (65-92. 95 per cent confidence limits).\"\n\nhttps://quadrant.org.au/opinion/qed/2021/01/covid-19-a-realistic-approach-to-community-management/",
"mediaType": "text/plain"
}
},
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1198373895515340800/activity"
},
{
"type": "Create",
"actor": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"object": {
"type": "Note",
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1198361278700146688",
"attributedTo": "https://www.minds.com/api/activitypub/users/1196069879724122124",
"content": "Growing Momentum for Ivermectin in German Press as Pharmacy Journal Introduces Ivermectin as Possible Treatment for COVID-19<br />Growing Momentum for Ivermectin in German Press as Pharmacy Journal Introduces Ivermectin as Possible Treatment for COVID-19<br /><br /><a href=\"https://trialsitenews.com/growing-momentum-for-ivermectin-in-german-press-as-pharmacy-journal-introduces-ivermectin-as-possible-treatment-for-covid-19/\" target=\"_blank\">https://trialsitenews.com/growing-momentum-for-ivermectin-in-german-press-as-pharmacy-journal-introduces-ivermectin-as-possible-treatment-for-covid-19/</a><br />",
"to": [
"https://www.w3.org/ns/activitystreams#Public"
],
"cc": [
"https://www.minds.com/api/activitypub/users/1196069879724122124/followers"
],
"tag": [],
"url": "https://www.minds.com/newsfeed/1198361278700146688",
"published": "2021-01-19T20:19:53+00:00",
"source": {
"content": "Growing Momentum for Ivermectin in German Press as Pharmacy Journal Introduces Ivermectin as Possible Treatment for COVID-19\nGrowing Momentum for Ivermectin in German Press as Pharmacy Journal Introduces Ivermectin as Possible Treatment for COVID-19\n\nhttps://trialsitenews.com/growing-momentum-for-ivermectin-in-german-press-as-pharmacy-journal-introduces-ivermectin-as-possible-treatment-for-covid-19/\n",
"mediaType": "text/plain"
}
},
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/entities/urn:activity:1198361278700146688/activity"
}
],
"id": "https://www.minds.com/api/activitypub/users/1196069879724122124/outbox",
"partOf": "https://www.minds.com/api/activitypub/users/1196069879724122124/outboxoutbox"
}